- Stocks
- Healthcare
- NYSE: ABBV

Price (delayed)

$108.08

Market cap

$191B

P/E Ratio

29.45

Dividend/share

$5.08

EPS

$3.67

Enterprise value

$264.59B

AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories. On October 19, 2011, Abbott Laboratories announced its plan to separate

ABBV's revenue is up by 48% year-on-year and by 7% since the previous quarter

ABBV's gross profit is up by 32% year-on-year and by 8% since the previous quarter

The EPS has grown by 32% from the previous quarter but it has contracted by 22% YoY

The company's net income rose by 29% QoQ but it fell by 4.2% YoY

AbbVie's equity has decreased by 15% YoY and by 8% from the previous quarter

The gross margin has contracted by 11% YoY

What are the main financial stats of ABBV

Market
Valuations
Earnings

Shares outstanding

1.77B

Market cap

$191B

Enterprise value

$264.59B

Price to earnings (P/E)

29.45

Price to book (P/B)

15.19

Price to sales (P/S)

3.56

EV/EBIT

31.21

EV/EBITDA

15.34

EV/Sales

4.92

Revenue

$53.73B

EBIT

$8.48B

EBITDA

$17.25B

Free cash flow

$19.57B

Per share
Balance sheet
Liquidity

EPS

$3.67

Free cash flow per share

$11.06

Book value per share

$7.12

Revenue per share

$30.37

TBVPS

$20.48

Total assets

$147.97B

Total liabilities

$135.38B

Debt

$82.14B

Equity

$12.57B

Working capital

-$2.69B

Debt to equity

6.53

Current ratio

0.91

Quick ratio

0.65

Net debt/EBITDA

4.27

Margins
Efficiency
Dividend

EBITDA margin

32.1%

Gross margin

65.6%

Net margin

12.4%

Operating margin

28.9%

Return on assets

4.5%

Return on equity

48.8%

Return on invested capital

10.2%

Return on capital employed

7.1%

Return on sales

15.8%

Dividend yield

4.7%

DPS

$5.08

Payout ratio

138.4%

How has the AbbVie stock price performed over time

Intraday

0.29%

1 week

0.76%

1 month

-8.72%

1 year

20.38%

YTD

0.87%

QTD

-4.05%

How have AbbVie's revenue and profit performed over time

Revenue

$53.73B

Gross profit

$35.26B

Operating income

$15.55B

Net income

$6.66B

Gross margin

65.6%

Net margin

12.4%

ABBV's revenue is up by 48% year-on-year and by 7% since the previous quarter

The operating income has grown by 42% YoY and by 31% from the previous quarter

The net margin has declined by 35% year-on-year but it rose by 20% since the previous quarter

ABBV's gross profit is up by 32% year-on-year and by 8% since the previous quarter

What is AbbVie's growth rate over time

What is AbbVie stock price valuation

P/E

29.45

P/B

15.19

P/S

3.56

EV/EBIT

31.21

EV/EBITDA

15.34

EV/Sales

4.92

The EPS has grown by 32% from the previous quarter but it has contracted by 22% YoY

ABBV's P/E is 25% above its 5-year quarterly average of 23.5 but 7% below its last 4 quarters average of 31.8

AbbVie's equity has decreased by 15% YoY and by 8% from the previous quarter

ABBV's price to book (P/B) is 12% higher than its last 4 quarters average of 13.6

ABBV's revenue is up by 48% year-on-year and by 7% since the previous quarter

ABBV's P/S is 13% below its 5-year quarterly average of 4.1 and 6% below its last 4 quarters average of 3.8

How efficient is AbbVie business performance

The ROS has contracted by 39% YoY but it has grown by 20% from the previous quarter

AbbVie's return on assets has decreased by 37% YoY but it has increased by 32% QoQ

The ROE has grown by 34% from the previous quarter

AbbVie's ROIC has increased by 31% from the previous quarter but it has decreased by 31% YoY

What is ABBV's dividend history

DPS

$5.08

Dividend yield

4.7%

Payout ratio

138.4%

Recent dividends

How did AbbVie financials performed over time

AbbVie's total assets is 9% higher than its total liabilities

The quick ratio has grown by 12% YoY and by 7% from the previous quarter

ABBV's current ratio is up by 10% since the previous quarter and by 6% year-on-year

AbbVie's equity has decreased by 15% YoY and by 8% from the previous quarter

The company's debt to equity rose by 10% YoY and by 4.6% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.